An Exploratory Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody) Combined With Chemotherapy in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 11 Sep 2018
Price : $35 *
At a glance
- Drugs Cetuximab biobetter (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Shanghai Henlius Biotech
- 30 Aug 2018 Status changed from not yet recruiting to recruiting.
- 12 Jul 2018 New trial record